Scholars Central

Conference abstractPublished 10 Sep 2018

Effect of intra-gastric balloon installation and laparoscopic sleeve gastrectomy to comorbidity reduction and cardiometabolic disease staging in 6 month after procedure

Authors: Makhmudov U M, Khashimov Sh Kh Khaybullina Z R, Sharapov N U, Sadikov N S, Kabulov T M, Tashkenbaev F R

Republican Specialized Center of Surgery named after academician V. Vakhidov, Uzbekistan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Achieving a weight loss is an important goal of bariatric surgery, given the increased risk for weight-related morbidity and mortality. The most common comorbidity at obesity is arterial hypertension, diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), depression. Article is devoted to evaluation of comorbidity in patients with obesity 3 after weight loss after Laparoscopic Sleeve Gastrectomy (LSG) and Intra-gastric Balloon Installation (IBI). Objective: To determine effect of Laparoscopic Sleeve Gastrectomy (LSG) and Intragastric Balloon Installation (IBI) to weight loss and comorbidity in patients with obesity 3. Methods: A total of 20 patients mean age 34.7±2.5 years; 80% female, BMI=49.4±2.5 kg/m2, 6 of them were with extremely high weight (BMI=62.1-75.4 kg/m2). Intra-gastric balloon (Allergan Inc., USA) was installed to patients with extremely high BMI (n=6), another patients were undergoing laparoscopic sleeve gastrectomy (n=14). Comorbidities were evaluated according to cardiometabolic disease staging. Results: It is established, that adiposity of 3 (BMI 49.4±2.5 kg/m2) associates with hyperlipidemia/hypertrigliceridemia in 85% of cases, diabetes mellitus-2/glucose intolerance- in 50%, arterial hypertension in 45%, Non-Alcoholic Fatty Liver Disease (NAFLD) in 35% of cases. Laparoscopic sleeve gastrectomy and intra-gastric balloon installation allow to achieve weight loss on 21.1% and 16.2% vs. initial weight, LSG and IBI were similar effective to weight loss (p>0.05) that caused decreasing of comorbidity: Glucose intolerance is reduced in 2 times, arterial hypertension in 3 times, dislipidemia in 1.9 times; NAFLD in 1.8 times in 6 months after intervention. LSG and IBI allow improving parameters on scale cardiometabolic disease staging, having achieved zero cardiometabolic risk at 35% of patients and at other patients’ transition in easier of its stage. Weight loss and reduction of comorbidity after LSG and IBI are combined with decrease of pro-inflammatory cytokines; IL-6, TNF-a and C-reactive protein in blood serum. Conclusion: LSG and IBI were similar effective to weight loss (p>0.05) that caused decreasing of comorbidity: Glucose intolerance is reduced in 2 times, arterial hypertension in 3 times, dyslipidemia in 1.9 times, NAFLD in 1.8 times in 6 months after intervention. IBI should be recommended as 1st step of obesity treatment in patients with extremely high weight, because this procedure cases decreasing of comorbidity and perioperative risk.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Obesity & Weight Loss Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Obesity & Weight Loss Therapy
  • SubjectObesity & Weight Management
  • BylineArticles whose byline prints “Makhmudov U M”
  • BylineArticles whose byline prints “Khashimov Sh Kh Khaybullina Z R”
  • BylineArticles whose byline prints “Sharapov N U”
  • BylineArticles whose byline prints “Sadikov N S”
  • BylineArticles whose byline prints “Kabulov T M”
  • BylineArticles whose byline prints “Tashkenbaev F R”